Priyanka Sharma, MD

Articles by Priyanka Sharma, MD

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

ByRadhika Appaya,Sarah Sammons, MD,Priyanka Sharma, MD,Yara Abdou,VK Gadi, MD, PhD,Taavy A. Miller,Spencer S. Langerman,Dominick Latremouille-Viau,Annie Guerin,Carmine Rossi,Emily McGovern,Gary Sopher,Vamsi Bollu,Natalia Bolotova,Şerban R. Iorga,Liz Santarsiero,Susan Dent, MD

June 30th 2025

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

BySara A. Hurvitz, MD,Michal Jarzab,Montserrat Munoz Mateu,Erin Cobain,Jin Zhang,Arielle Medford,Alistair Ring,Priyanka Sharma, MD,Christian Schem, MD,Ionut Temciuc,Zheng Li,Juan Pablo Zarate,Denise A. Yardley, MD

June 26th 2025

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Aditya Bardia, MD, MPH, FASCO,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Karen Afenjar,Murat Akdere,Juan Pablo Zarate,Yogesh Chattar,Peter A. Fasching

June 23rd 2025

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

ByAditya Bardia, MD, MPH, FASCO,Lajos Pusztai, MD, DPhil,Kathy S. Albain, MD,Kevin Kalinsky, MD, MS,Dawn Herman,William Barlow,Claudine Isaacs, MD,Micah Maxwell,Nadia Harbeck, MD, PhD,Priyanka Sharma, MD

April 27th 2023

The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients

ByMelissa P. Mitchell, MD, PhD,Priyanka Sharma, MD

June 15th 2018

This article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.

Latest Updated Articles

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
Published: June 26th 2025 | Updated:
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
Published: June 23rd 2025 | Updated:
The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients
Published: June 15th 2018 | Updated:

Priyanka Sharma, MD

Articles by Priyanka Sharma, MD

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients

Latest Updated Articles

Trending on CancerNetwork

FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

The Challenge of Making Bispecifics More Accessible in R/R Multiple Myeloma